Mark has over 30 years of leadership experience in the biopharmaceutical industry. He joined the Edison Oncology team in 2023; he focuses on business development and pre-commercial activities. Mark has a proven track record in launching and marketing therapies across orphan/rare diseases, acute care hospital settings, and large primary care markets.
Before joining Edison, Mark served as Chief Commercial Officer at Functional Fluidics, a company providing blood-based biomarkers to the biopharma industry with a focus on red blood cell health. From 2016 to 2021, he was Chief Investment Officer and Senior Vice President of Commercialization at Emmaus Life Sciences where he led all aspects of the company’s commercialization efforts. Prior to Emmaus, he was Vice President of Sales and Business Development at Targeted Medical Pharma.
Mark began his career at Sanofi, where he spent 15 years in various financial and commercial leadership roles. Throughout his career, he has built and led high-performing commercial teams across the biopharma sector.
In addition to his industry roles, Mark spent many years as a healthcare investment banker in New York City.
He holds a B.A. in Accounting and Information Systems from the City University of New York.